Particle concentration fluorescence immunoassay chemosensitivity assay for human epithelial ovarian cancer.
We adapted particle concentration fluorescence immunoassay technology to develop a new chemosensitivity assay. Six human epithelial ovarian cancer cell lines were incubated with cisplatin for 24 hours. Cells were then labeled with a fluorophore for 30 minutes. Removal of supernatant, washing of tumor cells, and reading of epifluorescence was performed automatically. Percent cell lysis was calculated simultaneously by chromium release assay. The particle concentration fluorescence chemosensitivity assay detected cell lysis in all six cell lines. The chemosensitivity assay detected a larger percent lysis than the chromium release assay in each of the cell lines. The advantages of our chemosensitivity assay are plating efficacy, speed, efficiency, safety, and accuracy.
Fanning
J
J
Division of Gynecologic Oncology, Southern Illinois University School of Medicine, Springfield.
Chapman
L
L
Meyers
W
W
Hilgers
R D
RD
D016923:Cell Death; D002461:Cell Line, Transformed; D002857:Chromium / Q000378:metabolism; D002945:Cisplatin / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D016231:Fluorescence Polarization Immunoassay / Q000379:methods; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology
D002857:Chromium; D002945:Cisplatin